Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study.
Nelli F, Giannarelli D, Fabbri A, Silvestri MA, Berrios JRG, Virtuoso A, Marrucci E, Schirripa M, Mazzotta M, Onorato A, Panichi V, Topini G, Pessina G, Natoni F, Signorelli C, Chilelli MG, Primi F, Ruggeri EM.
Nelli F, et al. Among authors: onorato a.
Ann Oncol. 2022 Jul;33(7):740-742. doi: 10.1016/j.annonc.2022.04.002. Epub 2022 Apr 9.
Ann Oncol. 2022.
PMID: 35413398
Free PMC article.
No abstract available.